Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways by Yajuan Su et al.
Su et al. Journal of Translational Medicine 2013, 11:132
http://www.translational-medicine.com/content/11/1/132RESEARCH Open AccessId1 enhances human ovarian cancer endothelial
progenitor cell angiogenesis via PI3K/Akt and
NF-κB/MMP-2 signaling pathways
Yajuan Su1†, Lingjuan Gao2†, Lichen Teng1, Ying Wang1, Jialin Cui1, Shiyun Peng1* and Songbin Fu3*Abstract
Background: Endothelial progenitor cells (EPCs) contribute to tumor angiogenesis and growth. We previously
reported that over-expression of an inhibitor of DNA binding/differentiation 1 (Id1) in EPCs can enhance EPC
proliferation, migration, and adhesion. In this study, we investigated the role of Id1 in EPC angiogenesis in patients
with ovarian cancer and the underlying signaling pathway.
Methods: Circulating EPCs from 22 patients with ovarian cancer and 15 healthy control subjects were cultured. Id1
and matrix metalloproteinase-2 (MMP-2) expression were analyzed by real-time reverse transcription-polymerase chain
reaction (RT-PCR) and western blot. EPC angiogenesis was detected by tube formation assays. Double-stranded DNA
containing the interference sequences was synthesized according to the structure of a pGCSIL-GFP viral vector and
then inserted into a linearized vector. Positive clones were identified as lentiviral vectors that expressed human Id1
short hairpin RNA (shRNA).
Results: Id1 and MMP-2 expression were increased in EPCs freshly isolated from ovarian cancer patients compared to
those obtained from healthy subjects. shRNA-mediated Id1 down-regulation substantially reduced EPC angiogenesis
and MMP-2 expression. Importantly, transfection of EPCs with Id1 in vitro induced phosphorylation of Akt (p-Akt) via
phosphoinositide 3-kinase and increased the expression of MMP-2 via NF-κB. Blockage of both pathways by specific
inhibitors (LY294002 and PDTC, respectively) abrogated Id1-enhanced EPC angiogenesis.
Conclusions: Id1 can enhance EPC angiogenesis in ovarian cancer, which is mainly mediated by the PI3K/Akt and
NF-κB/MMP-2 signaling pathways. Id1 and its downstream effectors are potential targets for treatment of ovarian
cancer because of their contribution to angiogenesis.
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Tumor angiogenesis is recognized as a critical step in
tumor progression through which an initially small,
localized or non-invasive tumor gradually develops into
a large, invasive, metastatic one. Previous studies have
shown that bone marrow (BM)-derived EPCs participate
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reproduction in any medium, provided the or[1-3]. Furthermore, EPCs control the angiogenic switch
in mouse lung metastasis [4]. Currently, the reasons for
ovarian cancer EPC angiogenesis are poorly understood.
Inhibitors of differentiation 1 (Id1) belong to the helix
loop helix (HLH) transcription factors family. Maw et al.
[5] showed that the level of Id1 expression was positively
related to the degree of malignancy in ovarian cancer. A
study by Lyden et al. [6] confirmed that Id1 and Id3 played
an important role in the vascular endothelial growth factor
(VEGF) signal pathway, which is related to angiogenesis.
In Id1 knock-out mice, it appeared that tumor growth was
significantly inhibited due to an angiogenesis defect. BM-
derived EPCs participated in the formation of new blood
vessels [7], suggesting that EPCs have a close relationshipThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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high expression of Id1 in EPCs derived from BM but not
in other cells, suggesting that Id1 might be a key factor for
EPCs. A defect of Id1 in BM could lead to decreased num-
bers of EPCs in peripheral blood, block tumor angiogen-
esis, and further suppress tumor development [8]. Thus,
Id1 may mediate angiogenesis of EPCs however, the
mechanism is still poorly understood.
In a previous study, we used real-time RT-PCR to exam-
ine mRNA expression of Id1 in EPCs of 25 patients with
ovarian cancer [9]. Western blot analysis revealed a higher
Id1 expression in human ovarian cancer EPCs than in cells
from 20 healthy controls. Compared to healthy controls,
ovarian cancer patients showed increased migration and
adhesion of EPCs. Statistical analyses revealed that ovarian
cancer enhanced proliferation, migration, and adhesion of
EPCs [9,10].
In the present study, we examined whether the over-
expression of Id1 can enhance angiogenesis in cultured
human ovarian cancer EPCs. We hypothesized that Id1 is
linked to the angiogenesis of ovarian cancer EPCs via regu-
lation of the NF-κB/matrix metalloproteinase-2 (MMP-2)
and PI3K/Akt pathways. Our in vitro data showed that Id1
up-regulated MMP-2 via a NF-κB–dependent mechanism
and simultaneously activated the Akt pathway via PI3K,
contributing to EPC angiogenesis. These findings show the
existence of an Id1/NF-κB/MMP-2/Akt signaling axis in
ovarian cancer EPC angiogenesis.
Methods
Patients
This study was approved by the local ethics committee
in China and informed consent was obtained from all
study participants. Twenty-two patients (median age, 46
years age range, 20–62 years) with histologically proven
ovarian cancer, including serous cancer (n=14), mucin-
ous cancer (n = 5), and endometrioid cancer (n = 3),
were studied along with a control group of 15 healthy
women (age range, 18–34 years). Patients who were di-
agnosed with ovarian cancer had no additional malig-
nant, inflammatory, or ischemic disease; wounds; or
ulcers that could influence the number of EPCs.
Cell culture
The Ethics Committee of the Harbin Medical University
approved the study protocol. EPC culture and identifica-
tion were described in our previous paper [9]. Total
mononuclear cells (MNCs) were isolated from 20 ml sam-
ples of human peripheral blood from patients with ovarian
cancer and healthy women by density gradient centrifuga-
tion with Histopaque-1077 (density 1.077 g/ml; Sigma).
MNCs were plated in 1 ml endothelial growth medium
(EGM-2; Lonza) on fibronectin-coated (Sigma) 24-well
plates. After 24 h of culturing, unattached cells werediscarded and attached cells were cultured as before.
Medium was replaced every 2 days thereafter, and each col-
ony/cluster was followed up. After 7 days in culture, colony
forming cells were recognized as attached spindle-shaped
cells. The adherent cells were incubated with DiI-acLDL
(Molecule Probes) and then fixed in 2% paraformaldehyde
and counterstained with fluorescein isothiocyanate (FITC)-
labeled lectin from Ulex europaeus agglutinin (UEA-1)
(Sigma). The fluorescent images were recorded under a
fluorescent microscope. Cells also were characterized by
immunofluorescence staining for von Willebrand factor
(vWF) and expression of CD31 and vascular endothelial
growth factor receptor-2 (VEGFR2) (Becton Dickinson).
Human umbilical vein endothelial cells (HUVECs)
(purchased from Cambrex Bio Science, Walkersville,
MD) were cultured in medium 199 containing 10% FBS,
penicillin (100 U/ml), streptomycin (100 mg/ml), hep-
arin (50 mg/ml), and endothelial cell growth supplement
(50 mg/ml). Third to seventh passages of HUVECs were
used for experiments. HUVECs were maintained in a 5%
CO2 incubator at 37°C.
Quantitative real-time RT-PCR
Total RNA isolation and cDNA synthesis from cultured
EPCs were performed using Trizol and the SuperScript II
Reverse Transcriptase kit (Invitrogen, USA) according to
the manufacturer’s instructions. Real-time PCR was
performed with the Mx3000p Real Time PCR System
(Stratagene, USA) using the following thermal cycling
conditions: 10 sec at 95°C followed by 40 cycles of 15 sec
at 95°C, 20 sec at 60°C, and 7 sec at 72°C. SYBR® GreenER
qPCR SuperMix Universal S (Invitrogen, USA) (25 μl)
were performed in triplicate. A no-template control (re-
placing RNA with water) was used as a negative control.
Id1, MMP-2 and MMP-9 mRNA in the EPCs was deter-
mined by relative quantitation, interpolating from a stand-
ard curve of template DNA of known concentration and
then normalized using β-actin as an internal control. Data
were analyzed by 2-ΔΔCt.







ATC-3; β-actin, 5-TGGCACCCAGCACAATGAA-3 and
5-CTAAGTCATAGTCCGCCTAGAAGCA-3.
Western blots
The EPCs were collected with sample buffer. Cell lysates
were centrifuged at 10000 g for 10 min at 4°C and the
supernatant was stored at −70°C. Protein concentrations
were determined with a Bio-Rad kit. 50-μg aliquots of
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Then the protein was blotted onto a polyvinylidene fluor-
ide (PVDF) membrane. Primary antibodies against Id1
(1:1000, Becton Dickinson), MMP-2 (1:1000, Becton
Dickinson), MMP-9 (1:1000, Becton Dickinson), Phospho-
65 (1:1000, Cell Signaling), Phospho-Akt (ser473) (1:1000,
Cell Signaling), Total-Akt (1:2000, Cell Signaling), and
β-actin (1:2000, Becton Dickinson) were used according to
the manufacturer’s recommendations. After washing the
membrane, a second antibody (HRP-conjugated anti-
mouse IgG) (1:2000, Becton Dickinson) was used to detect
Id1, mmp-2, mmp-9, p-65, Phospho-Akt, Total-Akt, and
β-actin. The bands were visualized using Pierce ECL
Western Blotting Substrate (Thermo Fisher Scientific Inc.,
Rockford, IL, USA) with 5 to 30 min exposure after wash-
ing the membrane. β-actin was used as the protein loading
control.
Molecular reagents
The Id1 cDNA from an ovarian cancer specimen was
cloned into a plasmid with enhanced green fluorescent
protein (GFP) (Clontech), and lentiviral vector express-
ing Id1-specific short hairpin RNA (shRNA) were
constructed as described previously (9). Pyrrolidine di-
thiocarbamate (PDTC) was used as an alternative inhibi-
tor of the NF-κB activity. LY294002 was used as a
specific PI3K inhibitor.
In vitro transduction of EPCs
For lentiviral transduction, the primary EPCs were pas-
saged into 6-well plates at a density of 1 × 105 cells/well.
When cells reached 30% confluence (typically on the
third day after subculturing), the medium was replaced
with 1 ml of fresh medium containing lentivirus at an
MOI of 150 and 6 μg/ml polybrene (Gikai gene com-
pany, Shanghai, China). The medium was replaced with
fresh medium on the following day. Five days after trans-
duction, cells were analyzed by flow cytometry using a
BD FACSCalibur™ cell analyzer (BD Biosciences). The
percentage of GFP-positive cells and mean fluorescence
intensity (MFI) of GFP-positive cells were determined
with WinMDI 2.8 software (J. Trotter, Flow Cytometry
Core Facility, Scripps Research Institute, La Jolla, CA).
Means and standard deviations from experiments
performed in triplicate are given.
In vitro tube formation
In vitro tube formation assay was performed using the
Matrigel basement membrane matrix (BD Biosciences).
1 ml/well Matrigel, kept on ice, was placed in 4-well cul-
ture plates. The plates were then incubated at 37°C for
30 min to allow Matrigel to solidify. About 2×104 FITC-
UEA-1-labeled EPCs were co-cultured with 4×104
HUVECs on the preplated Matrigel. The number ofFITC-UEA-1 EPCs incorporated to the tube was deter-
mined in five random high-power fields in duplicates. A
tube was defined as a structure exhibiting a length four
times its width.
Luciferase assays
Cells cultured in a 12-well plate with 60% confluence were
transfected with the Id1 cDNA at 1.4 μg/ml and co-
transfected with NF-κB luciferase/β-galactosidase re-
porters, at 1.4 μg/ml for 16 h in the transfection medium
and recovered in culture medium for 24 h. Cells were
harvested for luciferase assays, as previously described
[11]. The activity of NF-κB luciferase over β-galactosidase
(internal control) is presented as a relative luciferase activ-
ity. The Tropix dual reporter kit (Applied Biosystems) was
used with a Berthold TriStar flash injection luminometer.
Statistical analysis
Statistical analyses were performed with Statistical Pack-
age for Social Sciences 13.0 software program (SPSS,
USA). The Mann–Whitney U test and Student’s t-test
were used to compare variables between the two groups.
Multiple comparisons were analyzed by Anova followed
by post-hoc analysis to adjust the significance level. Data
are shown as means ± S.E. Statistical significance was con-
sidered as P < 0.05.
Results
Characterization of EPCs
After 7 days of culture, ex vivo expanded EPCs derived
from peripheral blood of healthy human volunteers and
patients with ovarian cancer exhibited spindle-shaped
morphology. EPCs were characterized as adherent and
double positive for Dil-Ac-LDL uptake and lectin binding
based on their appearance under a fluorescent micro-
scope. A total of 93.8 ± 4.5% of adherent cells showed
uptake of Dil-Ac-LDL and lectin binding after 7 days of
culture. The endothelial phenotype of these expanded
EPCs was further characterized by the expression of endo-
thelial markers such as vWF, CD31, and VEGFR2. Im-
munofluorescence showed that the cells were positive for
vWF, CD31, and VEGFR2 (Figure 1A).
We measured special molecular markers on the cell sur-
face by flow cytometry to identify EPCs. A specific mo-
lecular marker that can be used strictly to isolate EPCs
from other cells is lacking. EPCs can express various
markers at different stages during development. Moreover,
surface markers seems to differ in EPCs originating from
different sources, so there may not be a simple surface
marker on EPCs. However, CD34 and VEGFR-2 are widely
considered to be surface markers of EPCs. In this study,
we examined the expression of CD34 and VEGFR-2 on
adherent cells derived from mononuclear cells cultured
for 7 days using flow cytometry. The results showed that
Figure 1 Phenotypic characterization of EPCs from human peripheral blood. (A) After 1 week in culture, EPCs were stained with DIL-labeled
ac-LDL, FITC-conjugated Ulex europaeus lectin. vWF, VEGFR2 and CD31 analysis were assessed by immunofluorescence (× 20). (B) Detection of cell
markers on EPCs by flow cytometry, from left to right: isotype-negative control, the percentage of VEGFR2-positive cells, isotypenegative control
and the percentage of CD34-positive cells.
Figure 2 Id1 increases EPC angiogenesis. (A) Typical images of tube formation. (B) Id1 increases EPC angiogenesis. **p<0.01 vs. control, #, &p<0.05
vs. ovarian cancer.
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VEGFR2 -positive cells accounted for 80.37±4.03%
(Figure 1B). Thus, the EPCs isolated can be defined as
early-stage EPCs, although the CD34 expression of cells
was low, which can differentiate as endothelial cells.
Id1 increases EPCs angiogenesis in vitro
EPC angiogenesis functions in ovarian cancer were ex-
amined by assessing tube formation. Tube formation in
the Matrigel assay was markedly enhanced in EPCs.
(Figure 2). We next examined whether over-expression
of Id1 in EPCs can induce angiogenesis. Id1-LV and Id1-
RNAi-LV were constructed, as previously reported by us
(9). After the Id1-LV and Id1-RNAi-LV construct was
transfected into EPCs, we performed the EPC tube for-
mation analysis. Id1-LV and Id1-RNAi-LV were mark-
edly increased and reduced EPC tube formation. EPC
tube formation was significantly decreased by Id1
knock-down, compared to non-transfected control cells,Figure 3 Effects of LY294002 and PDTC on EPC angiogenesis function
p-Akt and t-Akt (β-actin is shown as a housekeeping control). (B) The graph
actin. The results are expressed as the mean ± S.E. **p<0.01 , *p < 0.05 vs.
formation assay. (D) Accumulated data showing EPCs angiogenesis functioas shown in Figure 2A-B. Taken together, these observa-
tions indicate that over-expression of Id1 can induce
angiogenic processes in EPCs.
PI3K/Akt and NF-kB are associated with Id1 and EPCs
angiogenesis
EPCs use a broad spectrum of angiogenesis mechanisms
to achieve enhanced tumor metastasis (8). To begin to
determine which signaling transduction pathways might
participate in Id1-mediated cell angiogenesis in EPCs,
we investigated the PI3K/AKT pathway using pharmaco-
logical inhibitors. Elevated AKT-Ser473 phosphorylation
was observed in EPCs, Id1-LV and Id1-RNAi-LV were
markedly increased and reduced AKT-Ser473 phosphor-
ylation in EPC (Figure 3A-B). EPCs that were transfected
with Id1 were used in tube formation assay. EPCs were
transfected with Id1 and then treated with PI3K inhibi-
tor (LY294002 at 50 μmol/L) and evaluated. LY294002
significantly reduced EPC tube formation by Id1s. (A) Typical western blot images showing protein expression of p-65,
showing the relative p-65 and p-Akt protein levels normalized to
control, #,&p < 0.05 vs. ovarian cancer. (C) Typical images of tube
ns. * , #,$ p<0.05 vs. ovarian cancer.
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EPC angiogenesis is mediated by the PI3K/AKT pathway.
Because expression of phosphorylated 65 was elevated in
EPCs (Figure 3A-B), we examined whether Id1 stimulation
could activate NF-kB in EPCs. Cells were transfected with
Id1 in the presence and absence of NF-κB inhibitors
PDTC. PDTC abrogated the Id1-induced angiogenesis as
judged by tube formation (Figure 3C-D). These data indi-
cate that Id1increases p-Akt and activates NF-κB, which
in turn increases EPC angiogenesis.
Id1 up-regulates MMP-2 via NF-κB in EPCs
MMP-2 and MMP-9 are MMPs that are relevant to angio-
genic processes. We examined MMP-2 and MMP-9 ex-
pression levels of EPCs. Basal expression levels of MMP-2
and MMP-9 mRNA and protein were significantly in-
creased in EPCs (Figure 4A-D). After the Id1-LV and Id1-Figure 4 Id1 regulates the expression of MMP-2 via NF-κB in EPCs. (A
expressed as means ± S.E. **p < 0.01 vs. control, #, &, $p < 0.05 vs. ovarian can
and MMP-9 (β-actin is shown as a housekeeping control). (C) The graph showi
The results are expressed as the mean ± S.E. **p < 0.01 vs. control, #,&,$p < 0.0
increased the promotor activity of NF-κB by luciferase assay. Increased promoto
*p < 0.05 vs. ovarian cancer, #p < 0.05 vs. Id1-LV.RNAi-LV construct was transfected into EPCs, we analyzed
EPC MMP-2 and MMP-9 expression levels. Id1-LV and
Id1-RNAi-LV, respectively, markedly increased and re-
duced EPC mRNA expression of MMP-2, but not MMP-9.
Compared to non-transfected control cells, expression of
MMP-2 was significantly decreased by Id1 knock-down, as
shown in Figure 4A-C.
Because MMP-2 and Id1 were correlated with each other
in EPCs, we postulated that Id1 might control the expres-
sion of MMP-2 in EPCs via NF-κB. To test this hypothesis,
EPCs were transfected with Id1, co-transfected with NF-κB
and β-galactosidase reporters, and harvested for evaluation
of NF-κB promoter activity by luciferase assays and of
MMP-2 by western blot. Id1 significantly increased NF-κB
promoter activity, whereas PDTC abrogated Id1-induced
NF-κB promoter activity (Figure 4D). Simultaneously, Id1
significantly increased the expression of MMP −2, and Id1-) MMP-2 and MMP-9 mRNA expression by real-time RT-PCR. Data are
cer. (B) Typical western blot images showing protein expression of MMP-2
ng the relative MMP-2 and MMP-9 protein levels normalized to β-actin.
5 vs. ovarian cancer. (D) Transfection of EPCs with Id1 significantly
r activity was abrogated by PDTC. RLA = relative luciferase activity.
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shown by western lot (Figure 4B-C). This suggests that Id1
increases the expression of MMP-2 via NF-κB.
Discussion
Angiogenesis is an important mechanism for tumorigen-
esis. Emerging evidence indicates that BM-derived EPCs
participate in the tumor vascular network in different ways.
They favor the formation of primitive tumor endothelium,
control tumor growth, and promote the establishment of
the pre-metastatic niche [12,13]. Moreover, the contribu-
tion of BM-derived EPCs to tumor neovascularization has
been reported in mice and humans [14,15]. In our previous
study, we found that EPCs from patients with ovarian
cancer transfected with Id1-RNAi-LV displayed less prolif-
eration, migration, and adhesion abilities compared to non-
transfected control cells [9]. The proliferation, migration,
and adhesion properties of ovarian cancer EPCs are attrib-
utable to the high expression of Id1, integrin α4 and p-Akt.
Id1 contributes to this angiogenesis via the PI3K/Akt and
integrin-α4 signaling pathways.
The molecular mechanism involved in EPC-induced
tumor angiogenesis is poorly understood. VEGF and pla-
cental growth factor (PlGF) have been shown to contrib-
ute to EPC mobilization and homing into tumors [16].
Several reports have implicated cytokines, chemokines,
hypoxia-inducible 1, integrin, and MMP-9 in regulating
tumor angiogenesis. Recent studies indicate that Id1
plays a role in BM-derived hematopoietic progenitor cell
mobilization [17-20]. In the present study, we demon-
strated that over-expression of Id1 alone can induce an-
giogenic processes of EPCs in ovarian cancer. Moreover,
knock-down of Id1 in EPCs almost completely abolished
the EPC angiogenic processes in ovarian cancer. These
findings indicate a crucial role for Id1 in ovarian cancer
EPCs. Id1-induced EPC angiogenesis is partially blocked
by the NF-κB inhibitor (PDTC) or the PI3K inhibitor
(LY294002). Activation of NF-κB by angiogenesis factors
in normal cells usually increases the expression of VEGF,
but not MMP-2. Interestingly, activation of NF-κB by
Id1 led to the high expression of MMP-2, instead of
VEGF, in EPCs from patients with ovarian cancer in the
present study. This may explain why Id1 transfectants
are tumorigenic.
Both Id1 and NF-κB are over-expressed in EPCs from
patients with ovarian cancer, which contributes to EPC
angiogenesis. NF-κB regulates MMP-2 [21], whereas Id1
strengthens this regulation via an increase of NF-κB
promoter activity, which contributes to an increase of
NF-κB constitutively. However, we could not exclude the
possibility that Id1 reduces the tumor volume by inhib-
ition of angiogenesis. Id1 has recently been recognized
as a clinical outcome predictor in esophageal squamous
carcinoma [22]. We believe that focusing on the entireId1/NF-κB/MMP-2 signaling pathway or downstream
key molecules specific for EPC angiogenesis is more
relevant to clinical prognosis than an upstream molecule
that has extensive effects on multiple signaling pathways.
Id1 is mainly expressed in cancer cells, but is occasion-
ally seen in epithelial basal cells and proliferating fibro-
blasts surrounding the tumor cells. The function of Id1
may also be offset by other HLH transcription factors,
such as E-box proteins, which are involved in cellular
differentiation acting against Id1 [23]. In ovarian cancer,
we have observed that some Id1-positive specimens are
associated with well-differentiated cancer cells. This sug-
gests that Id1 alone does not determine the cellular fate
(proliferation or differentiation). It seems that the inter-
action between Id1 and its antagonists (HLH transcription
factors) determines the cell fate. If this is true, Id1-
predominant ovarian cancer EPCs may not necessarily be
poorly differentiated but surely committed to cellular
angiogenesis.
Conclusion
In summary, these data support the rationale of pharmaco-
logic inhibition of the Id1/NF-κB/MMP-2 or Id1/PI3K/Akt
pathways for ovarian cancer therapy and suggest that inhib-
ition of Id1 or its downstream molecule MMP-2 removes
the protection of ovarian cancer EPC from angiogenesis.
Therefore, these EPC properties may be of significant clin-
ical utility for ovarian cancer radiochemosensitization to
improve long-term patient outcomes.
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